Prasad V - Search Results

1

Association of Adjuvant or Metastatic Setting With Discontinuation of Cancer Drugs in Clinical Trials.

Ahmed N, Vengalasetti Y, Haslam A, Prasad V. Ahmed N, et al. Among authors: prasad v. JAMA Netw Open. 2022 May 2;5(5):e2212327. doi: 10.1001/jamanetworkopen.2022.12327. JAMA Netw Open. 2022. PMID: 35576006 Free PMC article.

2

When is crossover desirable in cancer drug trials and when is it problematic?

Haslam A, Prasad V. Haslam A, et al. Among authors: prasad v. Ann Oncol. 2018 May 1;29(5):1079-1081. doi: 10.1093/annonc/mdy116. Ann Oncol. 2018. PMID: 29648572 Free PMC article. No abstract available.

3

Multivitamins Do Not Reduce Cardiovascular Disease and Mortality and Should Not Be Taken for This Purpose: How Do We Know That?

Haslam A, Prasad V. Haslam A, et al. Among authors: prasad v. Circ Cardiovasc Qual Outcomes. 2018 Jul;11(7):e004886. doi: 10.1161/CIRCOUTCOMES.118.004886. Circ Cardiovasc Qual Outcomes. 2018. PMID: 29991647 No abstract available.

4

A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology.

Haslam A, Hey SP, Gill J, Prasad V. Haslam A, et al. Among authors: prasad v. Eur J Cancer. 2019 Jan;106:196-211. doi: 10.1016/j.ejca.2018.11.012. Epub 2018 Dec 5. Eur J Cancer. 2019. PMID: 30528804

5

Where Does the Blame for High Health Care Costs Go? An Empirical Analysis of Newspaper and Journal Articles Criticizing Health Care Costs.

Haslam A, Crain T, Gill J, Herrera-Perez D, Prasad V. Haslam A, et al. Among authors: prasad v. Am J Med. 2019 Jun;132(6):718-721. doi: 10.1016/j.amjmed.2018.12.019. Epub 2019 Jan 9. Am J Med. 2019. PMID: 30639552

6

Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs.

Haslam A, Prasad V. Haslam A, et al. Among authors: prasad v. JAMA Netw Open. 2019 May 3;2(5):e192535. doi: 10.1001/jamanetworkopen.2019.2535. JAMA Netw Open. 2019. PMID: 31050774 Free PMC article.

7

Confirmatory Trials for Drugs Approved on a Single Trial.

Haslam A, Prasad V. Haslam A, et al. Among authors: prasad v. Circ Cardiovasc Qual Outcomes. 2019 Jun;12(6):e005494. doi: 10.1161/CIRCOUTCOMES.119.005494. Epub 2019 May 29. Circ Cardiovasc Qual Outcomes. 2019. PMID: 31137954 No abstract available.

8

Interpreting the Effectiveness of Cancer Screening From National Population Statistics: Is It Sound Practice?

Chapa J, Haslam A, Prasad V. Chapa J, et al. Among authors: prasad v. Mayo Clin Proc. 2019 Jun;94(6):951-956. doi: 10.1016/j.mayocp.2019.02.016. Mayo Clin Proc. 2019. PMID: 31171133 No abstract available.

9

A comprehensive review of randomized clinical trials in three medical journals reveals 396 medical reversals.

Herrera-Perez D, Haslam A, Crain T, Gill J, Livingston C, Kaestner V, Hayes M, Morgan D, Cifu AS, Prasad V. Herrera-Perez D, et al. Among authors: prasad v. Elife. 2019 Jun 11;8:e45183. doi: 10.7554/eLife.45183. Elife. 2019. PMID: 31182188 Free PMC article. Review.

10

Medical reversals in low- and middle-income countries.

Haslam A, Prasad V, Livingston C. Haslam A, et al. Among authors: prasad v. Int J Health Plann Manage. 2020 Mar;35(2):631-638. doi: 10.1002/hpm.2937. Epub 2019 Nov 11. Int J Health Plann Manage. 2020. PMID: 31710144

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,043 results

Search Page

Filters